Calcium channel blockers as potential therapeutics for obesity-associated autophagy defects and fatty liver pathologies

Autophagy

Volumn 10, Issue 12, 2014, Pages 2385-2386

  Park, Hwan Woo ^a,b   Lee, Jun Hee ^b  

^a Konyang University   (South Korea)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Autophagic flux; Calcium channel blocker; High fat diet; Lipotoxicity; NAFLD; Obesity; Protein inclusions; Verapamil

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; FAT DROPLET; PROTEIN P62; SATURATED FATTY ACID; SQSTM1 PROTEIN; UBIQUITINATED PROTEIN; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; HEPG2 CELL LINE; IN VITRO STUDY; INSULIN RESISTANCE; LIPID LIVER LEVEL; LIPOTOXICITY; LIVER CELL; LYSOSOME; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; ANIMAL; DRUG EFFECTS; FATTY LIVER; HUMAN; LIPID METABOLISM; METABOLISM; PATHOLOGY;

ANIMALIA;

ANIMALS; AUTOPHAGY; CALCIUM CHANNEL BLOCKERS; FATTY LIVER; HEPATOCYTES; HUMANS; LIPID METABOLISM; OBESITY;

EID: 84922116624     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/15548627.2014.984268     Document Type: Article

References (1)

1. Park HW, Park H, Semple IA, Jang I, Ro SH, Kim M, Cazares VA, Stuenkel EL, Kim JJ, Kim JS, Lee JH. Pharmacological correction of obesity-induced autophagy arrest using calcium channel blockers. Nat Commun 2014; 5: 4834; PMID: 25189398; http://dx.doi.org/10.1038/ncomms5834